Vor Ort
Merkzettel Warenkorb
Produktbild: Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease

Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease

Aus der Reihe Clinical Dilemmas

102,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.05.2016

Verlag

John Wiley & Sons

Seitenzahl

256

Maße (L/B/H)

24,4/18,5/1,5 cm

Gewicht

594 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-1-118-91203-4

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.05.2016

Verlag

John Wiley & Sons

Seitenzahl

256

Maße (L/B/H)

24,4/18,5/1,5 cm

Gewicht

594 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-1-118-91203-4

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: Libri GmbH

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease

  • List of Contributors vii

    Preface ix

    Part I: Nature of the condition

    1 Non-alcoholic fatty liver disease: Hype or harm? 3
    Stephen H. Caldwell and Curtis K. Argo

    2 NAFLD: A worldwide problem 8
    Joanna K. Dowman Geoffrey C. Farrell and Philip Newsome

    3 Is insulin resistance the principal cause of NAFLD? 15
    Ian F. Godsland Sanjeev Mehta Shareen Forbes Fabian Meienberg Michael Yee Simon D. Taylor¿Robinson and Desmond G. Johnston

    4 Paediatric NAFLD: A distinct disease with the propensity for progressive fibrosis 29
    Emer Fitzpatrick and Anil Dhawan

    5 Non¿alcoholic fatty liver disease (NAFLD) as cause of cryptogenic cirrhosis 36
    Jay H. Lefkowitch

    6 Is NAFLD different in absence of metabolic syndrome? 44
    Yusuf Yilmaz

    7 Occurrence of noncirrhotic HCC in NAFLD 50
    Dawn M. Torres and Stephen A. Harrison

    8 Fibrosis progression: Putative mechanisms and molecular pathways 61
    Wing¿Kin Syn and Anna Mae Diehl

    9 When is it NAFLD and when is it ALD?: Can the histologic evaluation of a liver biopsy guide the clinical evaluation? 72
    Elizabeth M. Brunt and David E. Kleiner                                                                                                                

    10 Of men and microbes: Role of the intestinal microbiome in non-alcoholic fatty liver disease 82
    Muhammad Bilal Siddiqui Mohammed Shadab Siddiqui and Arun J. Sanyal

    11 Can genetic influence in non¿alcoholic fatty liver disease be ignored? 91
    Yang¿Lin Liu Christopher P. Day and Quentin M. Anstee

    12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? 103
    Soo Lim

    Part III: Diagnosis and Scoring

    13 How to best diagnose NAFLD/NASH? 113
    Vlad Ratziu

    14 The clinical utility of noninvasive blood tests and elastography 124
    Emmanuel A. Tsochatzis and Massimo Pinzani

    15 Are the guidelines-AASLD IASL EASL and BSG-of help in the management of patients with NAFLD? 131
    Cristina Margini and Jean¿François Dufour

    16 Imaging methods for screening of hepatic steatosis 138
    Hero K. Hussain

    17 Are the advantages of obtaining a liver biopsy outweighed by the disadvantages? 152
    Jeremy F. L. Cobbold and Simon D. Taylor¿Robinson

    18 Screening for NAFLD in high¿risk populations 161
    Nader Lessan

    Part IV: Value of treatment measures

    19 Defining the role of metabolic physician 173
    Nicholas Finer

    20 Should physicians be prescribing or patients self¿medicating with orlistat vitamin E vitamin D insulin sensitizers pentoxifylline or coffee? 182
    Haripriya Maddur and Brent A. Neuschwander¿Tetri

    21 Effects of treatment of NAFLD on the metabolic syndrome 189
    Hannele Yki¿Järvinen

    22 What are the dangers as well as the true benefits of bariatric surgery? 196
    Andrew Jenkinson

    23 Liver transplantation: What can it offer? 203
    Roger Williams

    Part V: What does the future hold?

    24 Molecular antagonists leptin or other hormones in supplementing environmental factors? 211
    Jonathan M. Hazlehurst and Jeremy W. Tomlinson

    25 What is the role of antifibrotic therapies in the current and future management of NAFLD? 218
    Natasha McDonald and Jonathan Fallowfield

    26 Developmental programming of non¿alcoholic fatty liver disease 226
    Jiawei Li Paul Cordero and Jude A. Oben

    Index 232